General Updates

August 17, 2026 To, To, The Listing Compliance Department The Listing Department BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street Exchange Plaza, C-1, Block G Mumbai — 400001 Bandra Kurla Complex, Bandra (East) Scrip Code: 524632 Mumbai - 400051 Symbol: SHUKRAPHAR Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Media Coverage regarding NSE Listing and Company's Strategic Direction Dear Sir/Madam, Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Stock Exchanges that an article titled “Shukra Pharmaceuticals Charts Next Chapter at NSE with Medical Technology, Al and Innovation at the Centre” was published by ANI on August 14, 2026, and has subsequently been carried by various media platforms. The article covers the Company's recent listing on the National Stock Exchange of India Limited (NSE) and highlights the Company's strategic direction and its focus on Medical Technology, Artificial Intelligence, healthcare innovation and technology-enabled healthcare solutions. The Company is pleased to inform that, with its listing on the NSE on August 14, 2026, the Company's Equity Shares are now listed and available for trading on both BSE Limited and National Stock Exchange of India Limited, marking an important milestone in the Company's capital market journey. CIN : L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com The media coverage also refers to the Company's broader vision of leveraging technology, innovation, artificial intelligence and medical technology as part of its future growth and diversification strategy. The Company clarifies that the aforesaid media article is a media coverage of the Company's NSE listing and its strategic vision and does not represent any new material agreement, contract, order, acquisition, investment or other material transaction entered into by the Company, unless separately disclosed by the Company to the Stock Exchanges in accordance with applicable laws. The Company shall continue to make appropriate disclosures to the Stock Exchanges in accordance with Regulation 30 of the SEBI Listing Regulations and other applicable provisions, as and when any material event or development occurs. The aforesaid media coverage is being intimated to the Stock Exchanges for information and records. A copy of the said media article is enclosed herewith and can be fetched at following weblink: https://www.aninews.in/news/business/shukra-pharmaceuticals-charts-next-chapter-at-nse- with-medical-technology-ai-and-innovation-at-the-centre20260814195614/ Thanking you, Yours faithfully, For Shukra Pharmaceuticals Limited Name: Shivkant Dhaka8y Company Secretary and compliance officer ACS: 80894 Encl.A:s Above CIN : L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com